Related Experiment Videos
Induction of EAE in mice with recombinant human MOG, and treatment of EAE with a MOG peptide
B Devaux1, F Enderlin, B Wallner
1ImmuLogic Pharmaceutical Corporation, Waltham, MA 02154, USA.
Abstract:
Myelin oligodendrocyte glycoprotein (MOG) is a transmembrane glycoprotein expressed on the surface of central nervous system (CNS) myelin membranes, which has been shown to induce experimental autoimmune encephalomyelitis (EAE) in rodents. Here we describe the induction of EAE in SJL and (PLJ X SJL)F1 mice with truncated human recombinant MOG (thr-MOG, amino acids 1-120) which has been expressed in insect cells in soluble form. We show that in SJL mice, immunization with thr-MOG produces an immune response to the 1-30 and the 81-110 regions of the MOG molecule. We also demonstrate effective treatment of thr-MOG-induced EAE in SJL mice with intravenous injections of a single peptide, MOG 91-110. These results support the possibility of treating MS using an antigen dependent approach.
Insights
Researchers induced experimental autoimmune encephalomyelitis (EAE) using truncated myelin oligodendrocyte glycoprotein (MOG) in mice. Treatment with a specific MOG peptide effectively reduced EAE, suggesting antigen-specific therapy for multiple sclerosis (MS).
Area of Science:
- Neuroimmunology
- Autoimmune Diseases
Background:
- Myelin oligodendrocyte glycoprotein (MOG) is a key autoantigen in the central nervous system (CNS).
- MOG induces experimental autoimmune encephalomyelitis (EAE), a rodent model for multiple sclerosis (MS).
Purpose of the Study:
- To induce EAE using truncated human recombinant MOG (thr-MOG) in mice.
- To investigate the therapeutic potential of MOG peptides in treating MOG-induced EAE.
Main Methods:
- Induction of EAE in SJL and (PLJ X SJL)F1 mice using soluble thr-MOG.
- Analysis of immune responses to specific MOG regions.
- Treatment of thr-MOG-induced EAE with intravenous MOG peptide injections.
Main Results:
- Immunization with thr-MOG elicited immune responses targeting MOG regions 1-30 and 81-110 in SJL mice.
- Intravenous administration of MOG peptide 91-110 effectively treated thr-MOG-induced EAE in SJL mice.
Conclusions:
- Truncated MOG can induce EAE, mimicking aspects of MS.
- Antigen-specific immunotherapy using MOG peptides shows promise for treating MOG-associated CNS demyelinating diseases.